CCIA
KRYS icon

Campbell & Co Investment Adviser’s Krystal Biotech KRYS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.6M Buy
+17,795
New +$4.74M 0.26% 83
2025
Q4 		– Sell
-1,721
Closed -$304K – 1274
2025
Q3 		$304K Sell
1,721
-270
-14% -$40.4K 0.02% 910
2025
Q2 		$274K Buy
+1,991
New +$292K 0.02% 983
2024
Q2 		– Sell
-2,479
Closed -$441K – 1202
2024
Q1 		$441K Buy
+2,479
New +$344K 0.04% 753

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's KRYS Position: Q1 2026 in Review

Campbell & Co Investment Adviser opened a new position in Krystal Biotech (KRYS) in Q1 2026: 17,795 shares worth $4.6M. The stake represents 0.26% of the portfolio and ranks #83 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in KRYS as recently as Q3 2025.

Campbell & Co Investment Adviser first reported a position in KRYS in Q1 2024 and has held it in 4 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Campbell & Co Investment Adviser held 17,795 shares of Krystal Biotech worth $4.6M as of Q1 2026.
  • Krystal Biotech was a new Campbell & Co Investment Adviser position in Q1 2026.
  • Krystal Biotech made up 0.26% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #83 holding.
  • Campbell & Co Investment Adviser first reported a position in Krystal Biotech in Q1 2024 and has held it in 4 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.